ENGLEWOOD, CO / ACCESSWIRE / February 13, 2020 / Aytu BioScience, Inc. (NASDAQ:AYTU), a specialty pharmaceutical company focused on commercializing novel products that address significant medical needs, today will provide an overview of its business, including the company’s operational and financial results for its fiscal second quarter 2020 that ended December 31, 2019. The company will host a live conference call and webcast today at 4:30 p.m. ET. Conference call details are provided at the end of this press release.
2020 Second Quarter Financial and Corporate Highlights
Commenting on the second quarter of 2020, Josh Disbrow, Chief Executive Officer of Aytu BioScience, stated, “Revenue for the three months ended December 31, 2019 was $3.2 million, which represents 121% growth over the three months ended September 30, 2019. Considering that the Cerecor Rx portfolio purchase didn’t close until November, with the start of the integration beginning after that, this is a strong revenue number that we expect to grow with the product portfolio now integrated. We are not yet realizing the full benefit of the acquisition, so we look forward to our continued growth as we complete cross-training and maximize the multiple opportunities to gain synergy through our expanded Rx product portfolio.”
Conference Call Information
The company will host a live conference call at 4:30 p.m. ET today. The conference call can be accessed by dialing either:
1- 844-602-0380 (toll-free)
1- 862-298-0970 (international)
The webcast will be accessible live and archived on Aytu BioScience’s website, within the Investors section under Events & Presentations, at aytubio.com, for 90 days.
A replay of the call will be available for fourteen days. Access the replay by calling 1-877-481-4010 (toll-free) and using the replay access code 57940.
About Aytu BioScience, Inc.
Aytu BioScience is a commercial-stage specialty pharmaceutical company focused on commercializing novel products that address significant patient needs. The company currently markets a portfolio of prescription products addressing large primary care and pediatric markets. The primary care portfolio includes (i) Natesto®, the only FDA-approved nasal formulation of testosterone for men with hypogonadism (low testosterone, or “Low T”), (ii) ZolpiMist™, the only FDA-approved oral spray prescription sleep aid, and (iii) Tuzistra® XR, the only FDA-approved 12-hour codeine-based antitussive syrup. The pediatric portfolio includes (i) AcipHex® Sprinkle™, a granule formulation of rabeprazole sodium, a commonly prescribed proton pump inhibitor; (ii) Cefaclor, a second-generation cephalosporin antibiotic suspension; (iii) Karbinal® ER, an extended-release carbinoxamine (antihistamine) suspension indicated to treat numerous allergic conditions; and (iv) Poly-Vi-Flor® and Tri-Vi-Flor®, two complementary prescription fluoride-based supplement product lines containing combinations of fluoride and vitamins in various for infants and children with fluoride deficiency. Aytu’s strategy is to continue building its portfolio of revenue-generating products, leveraging its focused commercial team and expertise to build leading brands within large therapeutic markets. For more information visit aytubio.com.
Forward-Looking Statements
This press release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, or the Exchange Act. All statements other than statements of historical facts contained in this presentation, are forward-looking statements. Forward-looking statements are generally written in the future tense and/or are preceded by words such as ”may,” ”will,” ”should,” ”forecast,” ”could,” ”expect,” ”suggest,” ”believe,” ”estimate,” ”continue,” ”anticipate,” ”intend,” ”plan,” or similar words, or the negatives of such terms or other variations on such terms or comparable terminology. These statements are just predictions and are subject to risks and uncertainties that could cause the actual events or results to differ materially. These risks and uncertainties include, among others: the effects of the business combination of Aytu and the Commercial Portfolio and the previously announced, but not yet consummated, merger (“Merger”) with Innovus Pharmaceuticals, including the combined company’s future financial condition, results of operations, strategy and plans, the ability of the combined company to realize anticipated synergies in the timeframe expected or at all, changes in capital markets and the ability of the combined company to finance operations in the manner expected, the diversion of management time on Merger-related issues and integration of the Commercial Portfolio, the ultimate timing, outcome and results of integrating the operations the Commercial Portfolio and Innovus with Aytu’s existing operations, the failure to obtain the required votes of Innovus’ shareholders or Aytu’s shareholders to approve the Merger and related matters, the risk that a condition to closing of the Merger may not be satisfied, that either party may terminate the merger agreement or that the closing of the Merger might be delayed or not occur at all, the price per share utilized in the formula for the initial $8 million merger consideration in the Merger may not be reflective of the current market price of Aytu’s common stock on the closing date, potential adverse reactions or changes to business or employee relationships, including those resulting from the announcement or completion of the Merger, risks relating to gaining market acceptance of our products, obtaining or maintaining reimbursement by third-party payors, the potential future commercialization of our product candidates, the anticipated start dates, durations and completion dates, as well as the potential future results, of our ongoing and future clinical trials, the anticipated designs of our future clinical trials, anticipated future regulatory submissions and events, our anticipated future cash position and future events under our current and potential future collaboration. We also refer you to the risks described in ”Risk Factors” in Part I, Item 1A of the company’s Annual Report on Form 10-K and in the other reports and documents we file with the Securities and Exchange Commission from time to time.
Contact for Investors:
James Carbonara
Hayden IR
(646) 755-7412
james@haydenir.com
Aytu BioScience, Inc,
Condensed Consolidated Balance Sheet Information
|
|
December 31, | June 30, | ||||||
|
|
2019 | 2019 | ||||||
|
|
(Unaudited) | |||||||
|
Assets
|
||||||||
|
Current assets
|
||||||||
|
Cash and cash equivalents
|
$ | 5,259,492 | 11,044,227 | |||||
|
Restricted cash
|
251,396 | 250,000 | ||||||
|
Accounts receivable, net
|
5,197,151 | 1,740,787 | ||||||
|
Inventory, net
|
2,491,807 | 1,440,069 | ||||||
|
Prepaid expenses and other
|
2,361,249 | 957,781 | ||||||
|
Note receivable
|
1,350,000 | – | ||||||
|
Other current assets
|
1,426,617 | – | ||||||
|
Total current assets
|
18,337,712 | 15,432,864 | ||||||
|
|
||||||||
|
Fixed assets, net
|
122,064 | 203,733 | ||||||
|
Licensed assets, net
|
17,724,416 | 18,861,983 | ||||||
|
Patents, net
|
207,944 | 220,611 | ||||||
|
Right-of-use asset
|
374,568 | – | ||||||
|
Product technology rights
|
22,321,667 | – | ||||||
|
Deposits
|
2,200 | 2,200 | ||||||
|
Goodwill
|
15,387,064 | – | ||||||
|
Total long-term assets
|
56,139,923 | 19,288,527 | ||||||
|
Total assets
|
$ | 74,477,635 | $ | 34,721,391 | ||||
|
|
||||||||
|
Liabilities
|
||||||||
|
Current liabilities
|
||||||||
|
Accounts payable and other
|
$ | 9,598,567 | $ | 2,297,270 | ||||
|
Accrued liabilities
|
2,114,060 | 1,147,740 | ||||||
|
Accrued compensation
|
786,769 | 849,498 | ||||||
|
Current lease liability
|
82,755 | – | ||||||
|
Current contingent consideration
|
705,880 | 1,078,068 | ||||||
|
Current portion of fixed payment arrangements
|
2,661,456 | – | ||||||
|
Total current liabilities
|
15,949,487 | 5,372,576 | ||||||
|
|
||||||||
|
Long-term contingent consideration
|
17,739,964 | 22,247,796 | ||||||
|
Long-term lease liability
|
291,813 | – | ||||||
|
Long-term fixed payment arrangements
|
23,394,761 | |||||||
|
Warrant derivative liability
|
11,371 | 13,201 | ||||||
|
Total liabilities
|
57,387,395 | 27,633,573 | ||||||
|
|
||||||||
|
Commitments and contingencies
|
||||||||
|
|
||||||||
|
Stockholders’ equity
|
||||||||
|
Preferred Stock, par value $.0001; 50,000,000 shares authorized; shares issued and outstanding 10,215,845 and 3,594,981, respectively as of December 31, 2019 (unaudited) and June 30, 2019.
|
1,022 | 359 | ||||||
|
Common Stock, par value $.0001; 100,000,000 shares authorized; shares issued and outstanding 20,733,052 and 17,538,071, respectively as of December 31, 2019 (unaudited) and June 30, 2019.
|
2,073 | 1,754 | ||||||
|
Additional paid-in capital
|
128,619,922 | 113,475,205 | ||||||
|
Accumulated deficit
|
(111,532,777 | ) | (106,389,500 | ) | ||||
|
Total stockholders’ equity
|
16,758,367 | 7,087,818 | ||||||
|
|
||||||||
|
Total liabilities and stockholders’ equity
|
$ | 74,477,635 | $ | 34,721,391 | ||||
Aytu BioScience, Inc,.
Consolidated Statements of Operations Information
(Unaudited)
|
|
Three Months Ended December 31, | Six Months Ended December 31, | ||||||||||||||
|
|
2019 | 2018 | 2019 | 2018 | ||||||||||||
|
|
||||||||||||||||
|
Revenues
|
||||||||||||||||
|
Product revenue, net
|
$ | 3,175,236 | $ | 1,795,011 | $ | 4,615,062 | $ | 3,226,820 | ||||||||
|
|
||||||||||||||||
|
Operating expenses
|
||||||||||||||||
|
Cost of sales
|
606,046 | 525,138 | 981,766 | 936,097 | ||||||||||||
|
Research and development
|
66,675 | 149,029 | 144,695 | 304,907 | ||||||||||||
|
Selling, general and administrative
|
6,516,160 | 5,046,174 | 11,662,603 | 8,622,754 | ||||||||||||
|
Selling, general and administrative – related party
|
91,337 | 345,046 | ||||||||||||||
|
Amortization of intangible assets
|
953,450 | 534,063 | 1,528,567 | 986,020 | ||||||||||||
|
Total operating expenses
|
8,142,331 | 6,345,741 | 14,317,631 | 11,194,824 | ||||||||||||
|
|
||||||||||||||||
|
Loss from operations
|
(4,967,095 | ) | (4,550,730 | ) | (9,702,569 | ) | (7,968,004 | ) | ||||||||
|
|
||||||||||||||||
|
Other (expense) income
|
||||||||||||||||
|
Other (expense), net
|
(446,958 | ) | (127,569 | ) | (642,344 | ) | (204,130 | ) | ||||||||
|
Gain from derecognition of contingent consideration liability
|
5,199,806 | – | 5,199,806 | |||||||||||||
|
Gain from warrant derivative liability
|
– | 20,637 | 1,830 | 67,989 | ||||||||||||
|
Total other (expense) income
|
4,752,848 | (106,932 | ) | 4,559,292 | (136,141 | ) | ||||||||||
|
|
||||||||||||||||
|
Net loss
|
$ | (214,247 | ) | $ | (4,657,662 | ) | $ | (5,143,277 | ) | $ | (8,104,145 | ) | ||||
|
|
||||||||||||||||
|
Weighted average number of common shares outstanding
|
17,538,148 | 6,477,004 | 16,425,990 | 4,183,591 | ||||||||||||
|
|
||||||||||||||||
|
Basic and diluted net loss per common share
|
$ | (0.01 | ) | $ | (0.72 | ) | $ | (0.31 | ) | $ | (1.94 | ) | ||||
Aytu BioScience, Inc,
Condensed Consolidated Cash Flow Information
(Unaudited)
|
|
Six Months Ended December 31, | |||||||
|
|
2019 | 2018 | ||||||
|
|
||||||||
|
Operating Activities
|
||||||||
|
Net loss
|
$ | (5,143,277 | ) | $ | (8,104,145 | ) | ||
|
Adjustments to reconcile net loss to cash used in operating activities:
|
||||||||
|
Depreciation, amortization and accretion
|
2,157,540 | 1,230,671 | ||||||
|
Stock-based compensation expense
|
327,435 | 346,176 | ||||||
|
Derecognition of contingent consideration
|
(5,199,806 | ) | – | |||||
|
Issuance of common stock to employee
|
– | 11,690 | ||||||
|
Derivative income
|
(1,830 | ) | (67,989 | ) | ||||
|
Changes in operating assets and liabilities:
|
||||||||
|
(Increase) in accounts receivable
|
(3,456,364 | ) | (903,708 | ) | ||||
|
(Increase) in inventory
|
(132,199 | ) | (305,888 | ) | ||||
|
(Increase) in prepaid expenses and other
|
(171,430 | ) | (504,757 | ) | ||||
|
(Increase) in other current assets
|
(136,694 | ) | – | |||||
|
Increase in accounts payable and other
|
2,806,973 | 252,113 | ||||||
|
Increase in accrued liabilities
|
145,467 | 760,798 | ||||||
|
(Decrease) Increase in accrued compensation
|
(62,729 | ) | 203,160 | |||||
|
(Decrease) in fixed payment arrangements
|
(216,150 | ) | – | |||||
|
Increase in interest payable
|
– | 36,164 | ||||||
|
(Decrease) in deferred rent
|
(3,990 | ) | (1,450 | ) | ||||
|
Net cash used in operating activities
|
(9,087,054 | ) | (7,047,165 | ) | ||||
|
|
||||||||
|
Investing Activities
|
||||||||
|
Deposit
|
– | 2,888 | ||||||
|
Purchases of fixed assets
|
– | (12,954 | ) | |||||
|
Contingent consideration payment
|
(104,635 | ) | (50,221 | ) | ||||
|
Note receivable
|
(1,350,000 | ) | – | |||||
|
Purchase of assets
|
(4,500,000 | ) | (800,000 | ) | ||||
|
Net cash used in investing activities
|
(5,954,635 | ) | (860,287 | ) | ||||
|
|
||||||||
|
Financing Activities
|
||||||||
|
Issuance of preferred, common stock and warrants
|
10,000,000 | 15,180,000 | ||||||
|
Issuance costs related to preferred, common stock and warrants
|
(741,650 | ) | (1,479,963 | ) | ||||
|
Issuance of debt
|
– | 5,000,000 | ||||||
|
Net cash provided by financing activities
|
9,258,350 | 18,700,037 | ||||||
|
|
||||||||
|
Net change in cash, restricted cash and cash equivalents
|
(5,783,339 | ) | 10,792,585 | |||||
|
Cash, restricted cash and cash equivalents at beginning of period
|
11,294,227 | 7,112,527 | ||||||
|
Cash, restricted cash and cash equivalents at end of period
|
$ | 5,510,888 | $ | 17,905,112 | ||||
|
|
||||||||
|
Supplemental disclosures of cash and non-cash investing and financing transactions
|
||||||||
|
Cash paid for interest
|
$ | 161,890 | $ | – | ||||
|
Fair value of right-to-use asset and related lease liability
|
374,568 | – | ||||||
|
Issuance of Series G preferred stock due to acquisition of the Cerecor portfolio of pediatrics therapeutics (unaudited)
|
5,559,914 | – | ||||||
|
Inventory payment included in accounts payable
|
460,416 | – | ||||||
|
Contingent consideration included in accounts payable
|
16,014 | – | ||||||
|
Fixed payment arrangements included in accounts payable
|
291,666 | – | ||||||
|
Exchange of convertible preferred stock into common stock
|
319 | – | ||||||
|
Return deductions received by Cerecor
|
1,309,365 | – | ||||||
|
Fair value of warrants issued to investors and underwriters
|
– | 1,888,652 | ||||||
|
Issuance of preferred stock related to purchase of asset
|
– | 519,600 | ||||||
|
Contingent consideration related to purchase of asset
|
$ | – | $ | 8,833,219 | ||||
SOURCE: Aytu BioScience, Inc.
View source version on accesswire.com:
https://www.accesswire.com/576380/Aytu-Reports-Q2-Revenue-of-32M-Up-77-Year-over-Year-and-121-Sequentially
MEMPHIS, Tenn., July 5, 2024 /PRNewswire/ -- Methodist Le Bonheur Healthcare announced its four Memphis-based adult hospitals…
TEMPE, Ariz., July 5, 2024 /PRNewswire/ -- Economic activity in the hospital subsector grew in June…
mCare Digital unveils the mCareWatch MW-241 powered by KORE connectivity ATLANTA, July 5, 2024 /PRNewswire/…
Shareholders approved a dividend distribution of € 2.00 per ordinary share; representing an increase of…
Image acquisition and defocusing correction techniques enable observations of atomic-scale magnetic fields at never-before-seen resolution…
Marlborough, Massachusetts--(Newsfile Corp. - July 5, 2024) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO), a clinical…